In diabetic retinopathy, the NLRP3 inhibitor verapamil can significantly inhibit TLR4-mediated NLRP3 activation, reduce IL-1β and TNF-α levels and improve RGC survival (Eissa et al. 2021). This evidence concerns the gene NLRP3 and diabetic retinopathy.